Reports Q3 revenue $114.57M vs. $0 last year. As of September 30, 2025, Lipocine (LPCN) had $15.1M of unrestricted cash, cash equivalents and marketable investment securities compared to $21.6M at December 31, 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LPCN: